265 related articles for article (PubMed ID: 34433440)
1. Liquid biopsy posttreatment surveillance in endemic nasopharyngeal carcinoma: a cost-effective strategy to integrate circulating cell-free Epstein-Barr virus DNA.
Wu CF; Lin L; Mao YP; Deng B; Lv JW; Zheng WH; Wen DW; Kou J; Chen FP; Yang XL; Xu SS; Ma J; Zhou GQ; Sun Y
BMC Med; 2021 Aug; 19(1):193. PubMed ID: 34433440
[TBL] [Abstract][Full Text] [Related]
2. Prognostic potential of liquid biopsy tracking in the posttreatment surveillance of patients with nonmetastatic nasopharyngeal carcinoma.
Chen FP; Huang XD; Lv JW; Wen DW; Zhou GQ; Lin L; Kou J; Wu CF; Chen Y; Zheng ZQ; Li ZX; He XJ; Sun Y
Cancer; 2020 May; 126(10):2163-2173. PubMed ID: 32125701
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness analysis of combining plasma Epstein-Barr virus DNA testing and different surveillance imaging modalities for nasopharyngeal carcinoma patients in first remission.
Yang ZC; Nie ZQ; Chen QY; Du CC; Luo DH; Liu LT; Guo SS; Li JB; Sun R; Liu SL; Lu ZJ; Yuan L; Lu ZX; Mai HQ; Tang LQ
Oral Oncol; 2022 May; 128():105851. PubMed ID: 35430526
[TBL] [Abstract][Full Text] [Related]
4. Circulating Epstein-Barr virus DNA level post induction chemotherapy contributes to prognostication in advanced-stage nasopharyngeal carcinoma.
Chen FP; Luo YS; Chen K; Li JY; Huo LQ; Shi L; Ou-Yang Y; Cao XP
Eur J Cancer; 2021 Jul; 151():63-71. PubMed ID: 33964573
[TBL] [Abstract][Full Text] [Related]
5. Prospective study of tailoring whole-body dual-modality [18F]fluorodeoxyglucose positron emission tomography/computed tomography with plasma Epstein-Barr virus DNA for detecting distant metastasis in endemic nasopharyngeal carcinoma at initial staging.
Tang LQ; Chen QY; Fan W; Liu H; Zhang L; Guo L; Luo DH; Huang PY; Zhang X; Lin XP; Mo YX; Liu LZ; Mo HY; Li J; Zou RH; Cao Y; Xiang YQ; Qiu F; Sun R; Chen MY; Hua YJ; Lv X; Wang L; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Mai HQ
J Clin Oncol; 2013 Aug; 31(23):2861-9. PubMed ID: 23857969
[TBL] [Abstract][Full Text] [Related]
6. Improving on-treatment risk stratification of cancer patients with refined response classification and integration of circulating tumor DNA kinetics.
Lv J; Wu C; Li J; Chen F; He S; He Q; Zhou G; Ma J; Sun Y; Wei D; Lin L
BMC Med; 2022 Aug; 20(1):268. PubMed ID: 35996151
[TBL] [Abstract][Full Text] [Related]
7. The value of integrating tumor volume and plasma Epstein-Barr virus DNA load during sequential chemoradiotherapy for prognostic prediction and therapeutic guidance in high-risk locoregionally advanced nasopharyngeal carcinoma.
Wang G; Dong Z; Huang C; Du X; Chen L; Li K; Guo R; Tang L; Ma J
Oral Oncol; 2023 Oct; 145():106500. PubMed ID: 37467683
[TBL] [Abstract][Full Text] [Related]
8. Hopkins criteria for residual disease assessment after definitive radiotherapy in nasopharyngeal carcinoma.
Liu Y; Long W; Wang G; Yang Y; Liu B; Fan W
Cancer Med; 2020 Feb; 9(4):1328-1334. PubMed ID: 31875356
[TBL] [Abstract][Full Text] [Related]
9. Selectively recommend
Chen C; Xu T; Qiu X; Xie S; You Z; Hu Y; Zheng Y; Liang Z; Huang C; Chen T; Li L; Liu J; Fei Z
Radiat Oncol; 2021 Nov; 16(1):229. PubMed ID: 34838075
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness Analysis of Routine Magnetic Resonance Imaging in the Follow-Up of Patients With Nasopharyngeal Carcinoma After Intensity Modulated Radiation Therapy.
Zhou GQ; Wu CF; Zhang J; Mao YP; Tang LL; Chen L; Guo R; Ma J; Sun Y
Int J Radiat Oncol Biol Phys; 2018 Nov; 102(4):1382-1391. PubMed ID: 29804816
[TBL] [Abstract][Full Text] [Related]
11. Development and validation of a joint model for dynamic prediction of overall survival in nasopharyngeal carcinoma based on longitudinal post-treatment plasma cell-free Epstein-Barr virus DNA load.
Zhu GL; Fang XL; Yang KB; Tang LL; Ma J
Oral Oncol; 2022 Nov; 134():106140. PubMed ID: 36183501
[TBL] [Abstract][Full Text] [Related]
12. Identifying optimal candidates for induction chemotherapy among stage II-IVa nasopharyngeal carcinoma based on pretreatment Epstein-Barr virus DNA and nodal maximal standard uptake values of [
Xie HJ; Yu YF; Sun XS; Jia GD; Luo DH; Sun R; Liu LT; Guo SS; Liu SL; Chen QY; Tang LQ; Mai HQ
Cancer Med; 2020 Dec; 9(23):8852-8863. PubMed ID: 33034945
[TBL] [Abstract][Full Text] [Related]
13. Tumor heterogeneity measured on F-18 fluorodeoxyglucose positron emission tomography/computed tomography combined with plasma Epstein-Barr Virus load predicts prognosis in patients with primary nasopharyngeal carcinoma.
Chan SC; Chang KP; Fang YD; Tsang NM; Ng SH; Hsu CL; Liao CT; Yen TC
Laryngoscope; 2017 Jan; 127(1):E22-E28. PubMed ID: 27435352
[TBL] [Abstract][Full Text] [Related]
14. Plasma Epstein-Barr virus DNA screening followed by ¹⁸F-fluoro-2-deoxy-D-glucose positron emission tomography in detecting posttreatment failures of nasopharyngeal carcinoma.
Wang WY; Twu CW; Lin WY; Jiang RS; Liang KL; Chen KW; Wu CT; Shih YT; Lin JC
Cancer; 2011 Oct; 117(19):4452-9. PubMed ID: 21437892
[TBL] [Abstract][Full Text] [Related]
15. Value of early evaluation of treatment response using
Chen YH; Chang KP; Chu SC; Yen TC; Wang LY; Chang JT; Hsu CL; Ng SH; Liu SH; Chan SC
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):650-660. PubMed ID: 30264225
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness of Nasopharyngeal Carcinoma Screening With Epstein-Barr Virus Polymerase Chain Reaction or Serology in High-Incidence Populations Worldwide.
Miller JA; Le QT; Pinsky BA; Wang H
J Natl Cancer Inst; 2021 Jul; 113(7):852-862. PubMed ID: 33351145
[TBL] [Abstract][Full Text] [Related]
17. Complementary roles of MRI and endoscopic examination in the early detection of nasopharyngeal carcinoma.
King AD; Woo JKS; Ai QY; Chan JSM; Lam WKJ; Tse IOL; Bhatia KS; Zee BCY; Hui EP; Ma BBY; Chiu RWK; van Hasselt AC; Chan ATC; Lo YMD; Chan KCA
Ann Oncol; 2019 Jun; 30(6):977-982. PubMed ID: 30912815
[TBL] [Abstract][Full Text] [Related]
18. [Cost-effectiveness evaluation of seven screening strategies for nasopharyngeal carcinoma].
Rao DP; Liu Q; Cao SM
Zhonghua Zhong Liu Za Zhi; 2012 Jul; 34(7):549-53. PubMed ID: 22967476
[TBL] [Abstract][Full Text] [Related]
19. Prospective evaluation of plasma Epstein-Barr virus DNA clearance and fluorodeoxyglucose positron emission scan in assessing early response to chemotherapy in patients with advanced or recurrent nasopharyngeal carcinoma.
Ma B; Hui EP; King A; Leung SF; Kam MK; Mo F; Li L; Wang K; Loong H; Wong A; Chan CM; Chan KCA; Wong SCC; Lo YMD; Chan AT
Br J Cancer; 2018 Apr; 118(8):1051-1055. PubMed ID: 29555989
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of plasma Epstein-Barr virus DNA level during posttreatment follow-up in the patients with nasopharyngeal carcinoma having undergone intensity-modulated radiotherapy.
Li WF; Zhang Y; Huang XB; Du XJ; Tang LL; Chen L; Peng H; Guo R; Sun Y; Ma J
Chin J Cancer; 2017 Nov; 36(1):87. PubMed ID: 29116021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
